Apoyando a los profesionales de la oncología a través de la educación

El contenido de este sitio está destinado solo a profesionales de la salud

Regístrese gratis y obtenga acceso ilimitado a nuestra extensa biblioteca de elearning

Gane puntos CME y realice un seguimiento de su actividad de aprendizaje con cientos de horas de educación médica continua.

Registrate gratis

Integrating Updated Clinical Guidelines into Practice

The treatment landscape for UC, including muscle-invasive bladder cancer (MIBC), is rapidly advancing with new combination regimens, updated guidelines (e.g., ESMO), and a focus on multidisciplinary, personalised care. Immunotherapy-based combinations are now key in first-line treatment for advanced UC, aiming to improve survival and quality of life.

For MIBC, perioperative systemic therapies (neoadjuvant/adjuvant) are reshaping care by reducing recurrence and enhancing outcomes. Success depends on coordinated care among urologists, oncologists, and allied health professionals.

Managing adverse events (AEs) is crucial. Early recognition and proactive patient education help maintain treatment adherence and improve satisfaction.

This educational module supports best-practice adoption and informed, holistic UC care.

Integrating Updated Clinical Guidelines into Practice

Modulo

English

0 CME Points

Guardar Ver curso

Completo Completo

Público destinatarios

Healthcare professionals who aim to personalise treatment across the urothelial carcinoma spectrum while improving patient education, communication, and adherence to optimise treatment success.

Objetivos educativos

Equip healthcare professionals with the knowledge to align clinical decision-making with the latest updates in treatment guidelines for urothelial carcinoma.

Expected Practice Improvements:

Increased proficiency in applying guideline recommendations to tailor treatment approaches for individual patients.
Greater confidence in navigating changes in first-line and subsequent treatment pathways to improve clinical outcomes.
Describe the 2024–2025 ESMO interim changes for first-line advanced UC and when EV+P is an appropriate option.
Explain the rationale for early molecular testing (FGFR) and integrate results into treatment sequencing.
Summarise current perioperative systemic therapy options in MIBC and the role of MDT coordination.
Identify key adverse events for ADCs, ICIs and FGFR inhibitors and outline initial management steps.

Integrating Updated Clinical Guidelines into Practice

Público destinatarios

Objetivos educativos

Más sobre ecancer